6O6F

Co-crystal structure of Mcl1 with inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.6 Å
  • R-Value Free: 0.230 
  • R-Value Work: 0.220 

wwPDB Validation 3D Report Full Report


This is version 1.0 of the entry. See complete history

Literature

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

Caenepeel, S.Brown, S.P.Belmontes, B.Moody, G.Keegan, K.S.Chui, D.Whittington, D.A.Huang, X.Poppe, L.Cheng, A.C.Cardozo, M.Houze, J.Li, Y.Lucas, B.Paras, N.A.Wang, X.Taygerly, J.P.Vimolratana, M.Zancanella, M.Zhu, L.Cajulis, E.Osgood, T.Sun, J.Damon, L.Egan, R.K.Greninger, P.McClanaghan, J.D.Gong, J.Moujalled, D.Pomilio, G.Beltran, P.Benes, C.H.Roberts, A.W.Huang, D.C.Wei, A.Canon, J.Coxon, A.Hughes, P.E.

(2018) Cancer Discov 8: 1582-1597

  • DOI: 10.1158/2159-8290.CD-18-0387
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer. To overcome the significant challenges associated with inhibition of MCL1 protein-protein interactions, we rigorously applied small-molecule conformational restriction, whi ...

    The prosurvival BCL2 family member MCL1 is frequently dysregulated in cancer. To overcome the significant challenges associated with inhibition of MCL1 protein-protein interactions, we rigorously applied small-molecule conformational restriction, which culminated in the discovery of AMG 176, the first selective MCL1 inhibitor to be studied in humans. We demonstrate that MCL1 inhibition induces a rapid and committed step toward apoptosis in subsets of hematologic cancer cell lines, tumor xenograft models, and primary patient samples. With the use of a human MCL1 knock-in mouse, we demonstrate that MCL1 inhibition at active doses of AMG 176 is tolerated and correlates with clear pharmacodynamic effects, demonstrated by reductions in B cells, monocytes, and neutrophils. Furthermore, the combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses. These results highlight the therapeutic promise of AMG 176 and the potential for combinations with other BH3 mimetics. SIGNIFICANCE: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies. The synergistic combination of AMG 176 and venetoclax demonstrates robust activity in models of AML at tolerated doses, highlighting the promise of BH3-mimetic combinations in hematologic cancers. See related commentary by Leber et al., p. 1511 . This article is highlighted in the In This Issue feature, p. 1494 .


    Organizational Affiliation

    Amgen Research, Amgen Inc., Seattle, Washington.,Medicinal Chemistry, Amgen Inc., South San Francisco, California.,Department of Medical Biology, University of Melbourne, Melbourne, Australia.,Molecular Engineering, Amgen Inc., South San Francisco, California.,Amgen Research, Amgen Inc., South San Francisco, California.,Molecular Engineering, Amgen Inc., Cambridge, Massachusetts.,Department of Clinical Haematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Melbourne, Australia.,Oncology Research, Amgen Inc., Thousand Oaks, California. phughes@amgen.com seanpomeroy@yahoo.com.,Victorian Comprehensive Cancer Centre, Parkville, Australia.,Malignant Haematology and Stem Cell Transplantation Service, Alfred Hospital, Melbourne, Australia; and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia.,The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.,Genome Analysis Unit, Amgen Inc., Thousand Oaks, California.,Amgen Research, Amgen Inc., Thousand Oaks, California.,Medicinal Chemistry, Amgen Inc., Thousand Oaks, California.,Discovery Attribute Sciences, Amgen Inc., Thousand Oaks, California.,Oncology Research, Amgen Inc., Thousand Oaks, California.,Oncology Research, Amgen Inc., Seattle, Washington.,Medicinal Chemistry, Amgen Inc., Cambridge, Massachusetts.,Amgen Research, Amgen Inc., Thousand Oaks, California. phughes@amgen.com seanpomeroy@yahoo.com.,Amgen Research, Amgen Inc., Cambridge, Massachusetts.,Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Induced myeloid leukemia cell differentiation protein Mcl-1
A, B
158Homo sapiensMutation(s): 0 
Gene Names: MCL1 (BCL2L3)
Find proteins for Q07820 (Homo sapiens)
Go to Gene View: MCL1
Go to UniProtKB:  Q07820
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
LOD
Query on LOD

Download SDF File 
Download CCD File 
A, B
(3S)-5'-chloro-5-(cyclobutylmethyl)-2',3',4,5-tetrahydro-2H-spiro[1,5-benzoxazepine-3,1'-indene]-7-carboxylic acid
C23 H24 Cl N O3
YLXRDIJLTBHLLJ-QHCPKHFHSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.6 Å
  • R-Value Free: 0.230 
  • R-Value Work: 0.220 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 43.315α = 90.00
b = 84.935β = 90.00
c = 90.736γ = 90.00
Software Package:
Software NamePurpose
SCALEPACKdata scaling
AMoREphasing
CNXrefinement
DENZOdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2019-03-06 
  • Released Date: 2019-05-15 
  • Deposition Author(s): Huang, X.

Revision History 

  • Version 1.0: 2019-05-15
    Type: Initial release